CIVB vs CRD-B
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CIVB presents a conflicting profile: a weak Piotroski F-Score of 3/9 indicates deteriorating operational health, yet the company maintains a strong track record of earnings beats and an attractive valuation. Trading at a Price-to-Book of 0.91 and well below its Graham Number of $39.0, the stock is fundamentally undervalued from a defensive standpoint. However, the discrepancy between strong revenue growth (15.3%) and flat YoY earnings growth (-1.4%), combined with the low health score, suggests internal inefficiencies. The outlook is neutral as the valuation cushion battles operational weakness.
CRD-B exhibits significant valuation disconnects, trading at $9.94 despite a Graham Number of $5.58 and an Intrinsic Value of $2.73. While the Piotroski F-Score of 4/9 indicates stable health, this is offset by deteriorating fundamentals, including a -11.20% YoY revenue decline and a -21.1% YoY EPS drop. The technical trend is completely bearish (0/100), and the company has missed 3 of its last 4 earnings estimates. Despite a low forward P/E, the lack of actual growth makes the current premium unjustifiable.
Compare Another Pair
Related Comparisons
CIVB vs CRD-B: Head-to-Head Comparison
This page compares Civista Bancshares, Inc. (CIVB) and Crawford & Company (CRD-B) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.